Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL947340 | 0.98 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4HTR2AADRA2C | |
| Hydrochloric Acid SCHEMBL10513272 | 0.96 | SLC6A2 (0.37) | SLC6A2SLC6A3SLC6A4HTR2AADRA2C | |
| Hydrochloric Acid SCHEMBL3938043 | 0.94 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4HTR2AADRA2C | |
| SCHEMBL10511175 | 0.89 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AADRA2C | |
| SCHEMBL10510000 | 0.87 | HTR1D (0.40) | SLC6A2SLC6A3SLC6A4HTR2AADRA2C | |
| Hydrochloric Acid SCHEMBL10511305 | 0.85 | HTR1D (0.40) | SLC6A2SLC6A3SLC6A4HTR2AADRA2C | |
| SCHEMBL4315266 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AADRA2C | |
| SCHEMBL949891 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AADRA2C | |
| Hydrochloric Acid SCHEMBL10512940 | 0.82 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AADRA2C | |
| SCHEMBL7466842 | 0.81 | KDM4E (0.42) | SLC6A2SLC6A3SLC6A4HTR2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2406255-B1 | 4-OXADIAZOL-2-YL-INDAZOLES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2015-04-29 | — | — | EP | disclosed |
| US-8765743-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-01 | — | — | US | disclosed |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1552842-A1 | BICYCLIC PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-0858452-B1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2002-03-13 | — | — | EP | disclosed |
| CN-1070856-C | Thiazole derivatives | OTSUDA PHARMACEUTICAL CO LTD (JP) | 2001-09-12 | — | — | CN | disclosed |
| US-6140330-A | USEFUL AS PROTEIN KINASE INHIBITOR; FOR TREATMENT OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, MULTIPLE SCLEROSIS, PSORIASIS, ETC., VARIOUS ALLERGIC DISEASES SUCH AS CROHN'S DISEASE, ASTHMA | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-10-31 | — | — | US | disclosed |
| CN-1198160-A | Thiazole derivative | OTSUKA PHARMA CO LTD (JP) | 1998-11-04 | — | — | CN | disclosed |
| EP-0858452-A1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-08-19 | — | — | EP | disclosed |
| WO-1998004536-A1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1998-02-05 | — | — | WO | disclosed |
| US-4889857-A | BACTERICIDES; SIDE EFFECT REDUCTION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-12-26 | — | — | US | disclosed |
| EP-0311948-A2 | Quinolonecarboxylic acid compounds and pharmaceutical use thereof | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | SLC6A2 4789/4885SLC6A3 4578/4885SLC6A4 4840/4885 |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | SLC6A2 4789/4885SLC6A3 4578/4885SLC6A4 4840/4885 |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | SLC6A2 3228/4885SLC6A3 2598/4885SLC6A4 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.